

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No.: 120000000004711)
(Incorporated in the People's Republic of China)
(the "Company")

ANNOUNCEMENT IN RELATION TO TRADING HALT

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "**Company**") wishes to announce that it is currently exploring a possible private placement of new A-shares to be issued and listed on the Shanghai Stock Exchange (the "**Proposed Placement**"). As the Proposed Placement is only at a preliminary stage, in order to prevent any abnormal fluctuations in the prices of the Company's shares, the Company will be applying for a trading halt for its A-shares and S-shares, which are listed on the Shanghai Stock Exchange ("**SSE**") and Singapore Exchange Securities Trading Limited ("**SGX-ST**") respectively.

Pursuant to the listing rules of the SSE, the trading halt on the SSE will be for up to 5 market days, and may be extended (subject to SSE approval). As the Company will be applying for various PRC governmental approvals in relation to the Proposed Placement, the Company may apply for extensions of the trading halt on the SSE if it is unable to obtain the relevant PRC governmental approvals within the 5 market days.

Pursuant to the listing rules of the SGX-ST, the trading halt on the SGX-ST will be for up to 3 market days. The Company will make a further announcement on the trading halt on the SGX-ST within 3 market days.

By order of the Board

12 June 2014